Horizon 2020, the EU framework program for research and development, will grant 2.2 million euros to Lipum’s ongoing development of a biological pharmaceutical for treatment of chronic inflammatory diseases.Lipum has identified the novel target molecule Bile Salt-Stimulated Lipase (BSSL). Preclinical studies have very successfully verified the concept in several well-established models for autoimmune chronic inflammatory [...]